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Cervical cancer is a serious health burden worldwide, approximately 528 000 new cases 
and 266 000 deaths occurred in 2012. Despite the high mortality rate cervical cancer is 
highly preventable and treatable. The prevalence of cervical cancer in developed countries 
has decreased due to effective screening and vaccination programs, while the prevalence 
and mortality remains high in low- and middle- income countries due to the shortage of pre-
vention services and limited knowledge. The purpose of the final project is to describe evi-
dence-based knowledge about the prevention of cervical cancer. The aim of the literature 
review is to promote high quality care and health care education. The study question of the 
final project is: What are the best practices for the prevention of cervical cancer? 
 
This final project is an application of a systematic literature review, performed systematically 
by identifying, evaluating and summarizing the findings of 19 relevant evidence based stud-
ies of the topic.  
 
Vaccination and screening are the two most effective methods for decreasing the incidence 
and mortality of cervical cancer. An effective prevention strategy combines vaccination with 
well-organized national screening program. Vaccination programs have been proven to be 
cost-effective and potential to achieve high coverage. However, countries which have the 
highest burden of cervical cancer are dependent financial assistance in order to sustain a 
vaccination program. In many countries, significant cultural, ethical, social, infrastructural 
or/and practical barriers exist. These obstacles should be taken into account in order to 
implement a successful cervical cancer prevention. Additionally, several studies have noted 
that women generally have poor knowledge of risk factors and the causative relationship of 
HPV and cervical cancer.  Providing education for women is essential for increasing the 
knowledge, and screening and vaccination attendance. Nurses play an important role in 
promoting sexual health and providing the necessary education.  
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Kohdunkaulan syöpä on maailmanlaajuisesti valtava terveysongelma. Arvioiden mukaan 
vuonna 2012 ilmeni 528 000 uutta tapausta ja 266 000 kuolemaa. Korkeasta kuolleisuus 
luvusta huolimatta, kohdunkaulan syöpää on suhteellisen helppo ennalta-ehkäistä ja hoi-
taa. Kehittyneissä maissa kohdunkaulan syövän esiintyvyys on laskenut merkittävästi te-
hokkaiden seulonta ja HPV-rokotusohjelmien myötä, kun taas samaan aikaan keski- ja 
matalan tulon maissa kuolleisuus ja esiintyvyys luvut ovat edelleen korkeita. Tämän loppu-
työn tarkoitus on kuvata kohdunkaulan syövän ennalta-ehkäisyä tutkimukseen perustu-
vaan tietoon nojaten. Tavoitteena on tuoda tutkittua tietoa kohdunkaulan syövän ennalta-
ehkäisyn tueksi. 
Tutkimuskysymys on: mitkä ovat parhaat näyttöön perustavat hoitokäytänteet kohdun-
kaulan syövän ennaltaehkäisyssä? Tämä työ on sovellettu systemaattinen kirjallisuuskat-
saus, jonka aineisto on kerätty elektronisista tietokannoista (CINAH and MEDLINE).  Kirjal-
lisuuskatsaus tarkastelee 19 tieteellistä artikkelia. 
Rokottaminen ja seulonta ovat tutkimustulostemme mukaan kaksi tehokkainta tapaa vähen-
tää kohdunkaulan syövän esiintyvyyttä ja kuolleisuutta.  Tehokas ennalta-ehkäisy strategia 
on yhdistää rokottaminen ja hyvin organisoituun kansalliseen seulontaohjelmaan. Maat, 
joissa kohdunkaulan syöpä on suurin ongelma, tarvitsevat taloudellista tukea pystyäkseen 
ylläpitämään rokotusohjelman. 
Monissa maissa on myös todettu erilaisia kulttuurisia, eettisiä, sosiaalisia ja infrastruktuuriin 
liittyviä esteitä ennaltaehkäisylle. Jotta kohdunkaulan syövän ehkäisy voisi olla tehokasta, 
nämä esteet tulisi huomioida. 
Tutkimustulostemme mukaan naisilla on yleisesti puutteita riskitekijöiden ja kohdunkaulan 
syövän ja HPV infektion välisestä yhteydestä. Sairaanhoitajalla on tärkeä rooli kohdun-
kaulan syöpään liittyvän tietoisuuden kasvattamisessa. Sairaanhoitaja voi työssään mahdol-
lisuus kertoa rokottamisen ja seulonnan hyödyistä ja näin ollen lisätä osallistujalukuja 
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1 Introduction 
 
Cervical cancer is a serious health problem worldwide, approximately 528 000 new 
cases and 266 000 deaths occurred during 2012. Cervical cancer is one of the most 
common cancers among women and the fourth leading cause of the cancer death in 
women worldwide. High-risk regions of cervical cancer are Eastern Africa, Melanesia, 
Southern and Middle Africa. (Globocan 2012.) Approximately 88% of cervical cancer re-
lated deaths appear in developing countries (Singht, Azuine & Siahpush 2012:18). Dif-
ferences in prevalence’s and mortality rates between countries are shown in appendix 
1. Despite the high mortality rate, cervical cancer is highly preventable and treatable. 
The shortage of knowledge, access, resources and prevention services for cervical can-
cer are the main reasons for mortality and incidence rates are significantly greater in low- 
and middle- income countries than in high income countries. (SALC 2012; WHO 
2014:25.)  
The primary cause of cervical cancer is a human papillomavirus (HPV) infection. The 
infection is passed from one person to another through sexual contact (National Cancer 
Institute 2014). According to WHO (2014:7), incorporating HPV vaccinations into a na-
tional immunization program is an effective long-term plan in reducing cervical cancer 
prevalence and mortality; especially in developing countries. In many developed coun-
tries, the cervical cancer rate has decreased remarkably, in response to the cervical 
screening and treatment programs (WHO 2014:7). Since, the HPV vaccination cannot 
provide a protection against all HPV infections, nor treat pre-existing HPV infection it is 
essential to continue to vaccinate women and encourage them to undergo regular cervi-
cal cancer screening (National Cancer Institute 2014). According to an estimation, the 
vaccination prevents 70% of infections and screening more than 80% of cervical cancer 
cases and deaths (Duodecim 2013). Screening is an early detection method that can 
prevent a majority of cervical cancers. Recommended screening tests are visual inspec-
tions using acetic acid (VIA), cytology and HPV tests. In order to provide an effective 
cervical cancer prevention, women who test positive have to receive appropriate treat-
ment. (WHO 2014:10) 
Since HPV epidemics have a major public health influence, it is essential to screen and 
vaccinate the population from papillomaviruses (Vesterinen 2004:75). Nurses have a 
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significant role in providing information to women about cervical cancer and demonstrat-
ing the importance of the screenings and vaccinations (Schwaiger, Aruda, La Coursiere 
& Rubin 2011:417).  
 
This final project is a part of the MaZaFi network project between Malawi, Zambia 
and Finland. The project has existed since 2004 and it has expanded to become the 
MaZaFi3 project in 2013. The primary objective of the MaZaFi3 project is to promote 
high quality health care and education through active collaboration between Malawi, 
Zambia and Finland. The project emphasises theoretical understanding of the pro-
fessional nursing and clinical nursing skills. The aim of the project is to promote the 
knowledge and use of evidence-based practice research among nursing students 
and clinical staff by modern teaching methods. (CIMO 2013.) 
The purpose of the final project is to describe evidence-based knowledge about the 
prevention of cervical cancer and the aim of the literature review is to promote high 
quality care and health care education. The study question is: What are the best 
practices of cervical cancer prevention? 
 
Best practice refers to commercial or professional procedures which are accepted or 
prescribed to be most the correct or the most effective (Oxford Dictionaries 2015). In 
nursing care best practices are described to be evidence based recommendations 
accommodated into practice. In nursing care specific best practices are essential to 
standardize care and direct nurses to identify solution and problems. Although, when 
implementing best practice into nursing care it is important to acknowledge that the 
implementation involves more than just using evidence-based practice as a base of 
clinical decision. Considering patient’s preferences and values as a part of care is as 
well an essential part of implementing best practice. Thus, nursing care can be evi-
dence-based but it cannot be the best practice, if the needs and values of individuals 
are not noted. (Nelson 2014:1507-1516.) 
 
2 Prevention of cervical cancer 
 
The prevention of cervical cancer can be classified to primary prevention and secondary 
prevention. Primary prevention refers to preventing HPV infection and secondary refers 
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to detecting HPV infection and treating precursors of cervical cancer. Primary and sec-
ondary do not refer to ranking order or supremacy over one another.  
 
2.1 Prevention in nursing care 
 
Prevention in nursing care can be defined as an action targeted to prevent illness and 
promote health. Prevention is an essential part of cervical cancer nursing care, since 
cervical cancer is a highly preventable disease. Many lives and a lot of health care re-
sources can be saved by well targeted preventive care. In cervical cancer prevention, a 
nurse’s primary role is to raise cervical cancer awareness and educate people. A nurse's 
responsibility is to encourage patients to utilize preventive care services such as screen-
ing and vaccination. (WHO 2014:85.) 
 
Women’s knowledge of cervical cancer, risks, and their access to primary and secondary 
services in communities correlates with the success of the prevention of cervical cancer 
(SALC 2012:10). Each year, millions of people die due to preventable illnesses as a 
result of inadequate knowledge about the risk factors and preventive methods. Although 
many women have access to screenings they do not attend since they are unaware that 
cervical cancer is vastly preventable by screening and early treatment. (WHO 2014:84.) 
In prevention, nurses and other healthcare providers are in a first-hand position to pro-
vide knowledge to people (WHO 1946). 
 
2.1.1 Preventive health education 
 
Despite the high incidence of cervical cancer, there is limited awareness of the HPV 
infection, cervical cancer, risk factors and prevention throughout the world (SALC 
2012:3). According to Ports et al. (2013:630-645) and Francis et al. (2011:8760–8764) 
increasing the public’s knowledge towards cervical cancer should be one of major aims 
of the prevention. Greater knowledge enables women to make more informed decisions 
about their health. Health education provided to women should include the natural history 
of cervical cancer, information about HPV infection and its relation to cervical cancer, 
common risk factors and methods of control and the availability of prevention and early 
treatment (WHO 2014:66).  
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A nurse’s role is to provide quality health education to patients. Quality health education 
contains accurate information and its aim is to increase awareness, change attitudes and 
behaviors, and reduce incidence and mortality. Since, cervical cancer can be a delicate 
matter for women, it is important that nurses are able to provide information in a non-
judgemental way, with clear and sensitive language. Moreover, it is essential that the 
material provided is appropriate to the audience and tailored to local culture. (WHO 
2014:84-85.) According to Flores (2011:49) culturally tailored care can hinder the stress 
of a patient and their family improving the quality of care.  
 
Furthermore, one aspect of health education is to correct misbeliefs, reduce concerns 
and address the barriers that prevent women and families from acquiring preventive ser-
vices. The barriers can vary from fear of detection of the infection, shame of an intimate 
examination, pain or adverse effects to the cost of preventive interventions. To reduce 
concerns, nurses should educate parents about the safety and importance of the vac-
cination and screenings. Nurses should be aware that in some cultures family members, 
men or leaders of communities have a strong influence on the women’s health behavior. 
Men’s support or permission may be required when women and daughters attend to 
preventive services. Thus, health education should not only be targeted for women and 
girls, but also aimed to increase men’s knowledge as well. (WHO 2014: 81.) 
 
A nurse’s responsibility is to recognize the challenges, offer support and help women 
and families overcome them. (WHO 2014:79). Addressing ignorance, fears, embarrass-
ment and possible stigma may be crucial in order to provide effective health education. 
(WHO 2014:84-85.) Women’s role in society can also be utilized to promote cervical 
cancer education action. Ports et al. (2013:630-645) suggest that women could be edu-
cated as peer health leaders who could demystify cervical cancer, promote HPV vac-
cinations and provide a cost-effective means for health education delivery. Community 
leaders, teachers and traditional healers can also be trained to deliver information (WHO 
2014:87). 
 
2.2 Primary prevention; Vaccination 
 
The management of primary prevention can be performed in two ways, either through 
vaccination or controlling the risk factors. The risk factors can be controlled by educating 
women in how they can decrease the risk of transmission of the HPV infection. Reducing 
the risk of transmission involves reducing the number of sexual partners, vaccination and 
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condom usage. HPV vaccines provide a protection against specific types of human pap-
illomaviruses. Currently there are two HPV vaccines in the market: the quadrivalent vac-
cine Gardasil and the bivalent vaccine Cervarix. Gardasil builds a protection against four 
high-risk HPV types: 6, 11, 16 and 18, while Cervarix protects against two high-risk type 
HPVs; 16 and 18. According to estimations 70% of all cervical cancers root from types 
16 and 18. (National Cancer Institute 2014.)  
 
Based on current knowledge, the most effective primary prevention method for HPV in-
fection is vaccination (SALC 2012:10). The National Cancer Institute (2014) states that 
HPV vaccination has the potential to reduce cervical cancer deaths among women 
around the world by as much as two-thirds, assuming that all women would be vac-
cinated and the protection would be long-term. Vaccination would be beneficial finan-
cially in most of the countries, since high vaccination rates can reduce healthcare costs 
and reduce the need for medical care, biopsies and invasive procedures associated with 
follow-up from abnormal screening tests. (National Cancer Institute 2014.) Furthermore, 
in areas where women have a limited access to screenings, vaccination alone can sig-
nificantly reduce the cervical cancer rates (Lehtinen, Namujju, Sellors and Lehtinen 
2011). 
 
Different approaches for initiating vaccination programmes have been conducted in dif-
ferent countries. In 2013, the HPV vaccination was included in the national vaccination 
programme in Finland. All girls aged 11-13 were vaccinated and “catch-up” vaccinations 
were performed for girls aged 12-16 in 2013-2014. (THL 2013.) To standardize the vac-
cination programmes WHO has developed a comprehensive cervical cancer prevention 
and control programme, which is recommended to be used as a base of any national or 
regional prevention plan.  According to WHO (2014:99) the recommended age for vac-
cination is between ages 9-13, prior to a girl’s sexual debut.  Two doses would be suffi-
cient for girls under 15 years, three for those older than 15.  
 
Although, vaccination is a cost-effective method to prevent cervical cancer, some of the 
middle and low-income countries are not financially capable to provide a vaccination 
program to their citizens (Van Kriekinge, Castellsague, Cibula & Demarteau 2014:733; 
Kim, Campos, O'Shea, Diaz & Mutyaba 2013:60-72). To decrease the burden of cervical 
cancer the Global Alliance of Vaccination and Immunization (GAVI) financially supports 
HPV vaccinations for certain countries with the lowest income (Ports, Reddy and 
Rameshbabu 2013:630-645).   
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2.3 Secondary prevention; Screening 
 
 
Half a century ago, cervical cancer caused the most cancer deaths in women in United 
States. The initiation of the Pap smear screening program in 1945 reduced the women's 
cervical cancer mortality by 70%. (Schwaiger et al 2011:417.) In Finland screening pre-
vents more than 80% of cervical cancer cases and deaths when treated appropriately. 
(Käypä hoito 2010) 
 
Secondary prevention strategies of cervical cancer includes screening, early detection 
and treatment of precancerous lesions. Screening and early detection should be closely 
related to the treatment, since screening or early detection alone do not have preventive 
value. By screening, cervical cancer and pre-cancer stages can be detected. When can-
cer is detected in its early stages, effective treatment can be initiated. (WHO 2014:124.) 
Available screening methods for women are Papanicolaou (Pap) smear screening (cy-
tology), visual inspection and HPV testing. The Pap smear is a conventional method 
which diagnoses cancer and pre-cancer by examining changes of cervical cells (SALC 
2012:11.) Liquid-based cytology is an alternate option to conventional methods. The 
sample provides a lower rate of unsatisfactory specimens, it is quicker and it can be used 
to test for HPV DNA and other STIs. However, cytology-based screening tests are ex-
pensive, technical to implement and require a second visit in case the test is positive. 
(WHO 2014:133.) Based on solid evidence, screening via regular gynecologic examina-
tions and cytological testing with treatment of precancerous abnormalities decreases the 
incidence and mortality of cervical cancer (National Cancer Institute 2014). 
 
Screening with visual inspection can be done with acetic acid (white vinegar) or with 
Lugol’s iodine in order to identify the diseased area. When acetic acid interacts with the 
infected area, the area appears whiter than the rest of the cervix. As this method is not 
laboratory dependent and does not require expensive infrastructure, it is a good and 
feasible alternative for most developing countries. (SALC 2012:11.)  
 
Molecular HPV DNA testing detects high-risk types of human papillomaviruses. HPV 
testing requires good infrastructure and is relatively expensive. However, a new tech-
nique which does not require electricity and is non-technical is emerging. The new tech-
nique may become a good option in low-resource settings. In future it is likely that testing 
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samples are self-collected by women themselves, which would ease the access of cer-
vical screening for women who are unwilling to participate in cervical examination by 
health care professionals and as well decrease the need for medical personnel. (SALC 
2013:14; WHO 2014:130)  
 
The frequency of screenings and age of onset varies in different countries. According to 
WHO (2014:207) it is recommended women to be screened at least once between the 
ages 30 and 49 (see figure 1). Usually the initiation age is between 21 and 25 (35 in 
developing countries) and the frequency of the interval should be less than five years 
until the age of 60. Women under 25-years old should be screened only if they have had 
previous abnormal screening results, multiple partners, early sexual exposure or have 
been diagnosed as HIV-positive. (FIGO 2009.)  
 
Screening programmes have a potential to decrease cervical cancer incidence and mor-
tality significantly if implemented correctly. Women who do not have access to cervical 
cancer screenings have a significantly higher risk of developing cervical cancer (Francis 
et al. 2011:8760–8764; WHO 2014:3). Additionally, as the vaccines do not protect 
against all of the high-risk HPV infections, it is important for vaccinated women 
to continue undergoing regular cervical cancer screening (National Cancer Institute 
2014).  
 
2.4 Barriers to prevention 
 
Despite the prosperous outcomes of the primary and secondary prevention strategies, 
there are many limitations for prevention, which affect women's screening and vaccina-
tion behavior. Barriers to prevention include limited access to medical care, (especially 
in rural areas); cultural beliefs and expectations; foreign or formal language; limited 
knowledge; fear; embarrassment; ignorance and the lack of the financial resources (Er-
sin and Bahar 2013:4977-829; Francis et al. 2011; Ports et al. 2013:630-645; SALC 
2012; Natunen et. al 2011). Also the lack of infrastructure, laboratories, healthcare pro-
fessionals, health insurance,  transportation, female doctors and concerns related to the 
safety and side-effects of vaccination and screening were noted as barriers to prevention 
(Chan, Chan, Ng & Wong 2012:481-485; Ersin & Bahar 2013:4977-4982; Sadler, Albrow, 
Shelton, Kitchener & Brabin 2011:41-45; Kane 2012:24-29). In addition, SALC (2012:8) 
states that, in some region and in patriarchal cultures, women’s position in a society is 
limited and women may not be on charge of their health behavior. Women’s sex related 
 
 tailored to age 
and cultur 
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decisions may be significantly influenced by their parents, family, culture, husbands and 
other authorities. (Ersin & Bahar 2013:4977-4829) When planning prevention strategies, 
these attributes needs to be considered. In addition, the prevention strategies should 
always be adjusted to correspond the regional and cultural special demands. (Lehtinen, 
Namujju, Sellors & Lehtinen 2011) 
3 Background 
 
3.1 Relationship between cervical cancer and human papillomavirus 
 
Cervical cancer is a slow-growing cancer, which forms in a tissues of a woman’s cervix. 
The primary cause of cervical cancer is a human papillomavirus (HPV) infection. (SALC 
2012:8; WHO 2014:23.) According to current knowledge, there are more than 200 differ-
ent types of human papillomaviruses, of which more than 40 types have potential to 
cause infection, warts or papillomas in the anogenital region. 14 types of HPV have been 
associated with certain types of cancer. Numerous studies have detected that 70% of 
cervical cancers worldwide have been caused either by HPV type 16 or 18. (Greener 
2014:378; National Cancer Institute 2014.)  
 
HPV infection is a common sexually transmitted infection worldwide (WHO 2014:23). 
Approximately all women and men are infected by HPV at least once in their life span. 
However, most infections never develop to the cancer stage (WHO 2014:37) as approx-
imately 80-90% HPV infections heal spontaneously by immune system suppression 
within two years (Reunala et al.  2003:65; Teitelman, Stringer, Averbutch & Witkoski 
2009:70; WHO 2014:37).   
 
 
3.2 Risk factors for cervical cancer 
 
According to several studies there are certain risk factors that can be associated with 
cervical cancer. Risk factors that increase the risk the of a woman to develop cervical 
cancer include: an early sexual life, unprotected sex, multiple partners, HIV, a weak im-
mune system, smoking, genes (type HLA), other concurrent sexually transmitted dis-
eases, breakage of the skin, multiple labors, chronic inflammation and long term contra-
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ceptive use. (Joensuu, Roberts & Teppo 1999:387; National Cancer Institute 2014; Re-
unala et al. 2003:65; SALC 2012:8.) Most of the risk factors can be linked to the immune 
suppression, however it is still unclear why the use of contraceptives increases the cer-
vical cancer risk. Some researchers believe that the effect is indirect, an average woman 
who is on the pill goes to screenings more often and they are more sexually active. (Can-
cer Research UK 2014.) 
 
3.3 Symptoms of HPV infection and cervical cancer 
 
Generally the progress of developing cervical cancer is slow and takes approximately 10 
to 20 years (WHO 2014:23). Women in early phases of cervical cancer are usually 
asymptomatic. Typically the first symptoms appear after the cancer has reached the in-
vasive stage. Early symptoms include: abnormal discharge from vagina, bleeding after 
intercourse, pain during the intercourse and increased bleeding during periods. (Ameri-
can Cancer Society 2014.) Some women experience lower abdominal pain, lower back 
pain or problems to urinate during the later stages of cervical cancer (Duodecim 2014). 
 
4 Purpose, aim and the study question of the final project 
 
The purpose of the final project is to describe evidence-based knowledge of the preven-
tion of cervical cancer and the aim of the literature review is to promote high quality care 
and health care education. The study question is: What are the best practices of the 
prevention of cervical cancer? 
5 Methodology 
 
 
5.1 Literature review 
 
The literature review is an organized, comprehensive and systematically written interpre-
tation of existing literature that addresses a specific topic (Aveyar 2014:15; LoBiondo-
Wood & Haber 2006:79; Burns & Grove 2005:93). The primary aim of a literature review 
is to present a reliable evidential summary of past research (Holly, Salmond & Saimbert 
10 
 
2011:16). In health science the object of a literature review is to present knowledge which 
promotes nursing practice and evidence-based care in nursing research. Currently, evi-
dence-based practice within social and health care has a growing demand, since it has 
been proven to increase the quality of clinical decision making and outcomes of the 
health care of patients. (Aveyar 2014:15; Holly et al. 2011:5.) 
 
The process of this literature review starts from the identification of the study question. 
After the study question is identified, the question is answered by analysing collected 
data, using a systematic approach (Aveyar 2010:6). In order to make the database 
search, concepts and keywords are identified. Sources gathered from a database search 
are assessed against the inclusion criterias and accepted or discarded accordingly. Then 
the relevancy of the references are assessed and chosen material organised, coded and 
analysed (See figure 2). (Polit & Becks 2004:111.) Finally, the literature review is written 
in a systematic and coherent manner. The results are compared and the similarities and 
disparities are outlined. In addition the limitations, incoherence and variables of the stud-
ies are acknowledged and rational given where possible. (Cronin, Ryan & Coughlan 
2008:43.) In this final project the principles of a systematic literature review were applied. 
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Figure 2. Flow of tasks in a literature review applied from Polit & Beck 2004:108 
 
 
 
5.2 Database search 
 
We aimed to implement a database search throughout the process. A tentative search 
was carried out at the beginning of the process in order to gain sufficient information for 
creating an overall picture of the topic. The framework of the topic made forming the aim, 
purpose and study question possible. Keywords utilised in a first search were cervical 
cancer, HPV, HPV vaccination, cervical screening, Pap smear, prevention, screening 
guidelines, Africa, cervical cancer prevention, Malawi, Zambia and Sub-Saharan Africa. 
Searches made in first phase were restricted to results with ‘abstracts available’ in the 
years between 2009 and 2014. The search engines that were used were: CINAHL and 
MEDLINE. In addition, articles, brochures and news from the internet were used to 
gather background information. 
 
The aim of the second phase “Designing the plan for the final project” was to specify the 
search to be more specific. The specification was implemented by redefining the key-
words. After first phase, the study question and the purpose of the final project was ex-
panded to include the English speaking world. At the beginning the focus was only within 
MaZaFi countries. Thus, keywords concerning African countries were excluded and key-
words, such as nursing and health promotion, were added. Search engines that were 
employed in this phase include CINAHL, MEDLINE, TERKKO, MEDIC, PUBMED and 
SCIENCEDIRECT. Searches in the second phase were limited to the past five years 
(2009-2014), abstract available and empirical studies.  
 
During the third phase “Implementing the final project” literature reviews were included 
to the research. This decision was made because most of the empirical studies that were 
found, focused only on a specific region or country rather than on the global prevention 
of cervical cancer. At this phase article analyses were carried out and the forming of a 
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theory for the results initiated. Findings of the articles were categorized and coded and 
the similarities and inconsistencies were recognized. The search engines MEDLINE and 
CINAHL were utilized in this stage because using all the search engines mentioned in 
second phase gave a vast amount of hits and, considering the limited time given, it would 
have been impossible to analyse those properly. Keywords used in the search were cer-
vical cancer, prevention, nursing, health promotion, screening, vaccination and best 
practice. Limitations were for English language articles from the past five years with ab-
stract available. 
 
5.3 Database search 
 
The following inclusion criterias were used: 
 
 The article answers the study question 
 The article had a relevant heading and abstract 
 It was published during the past five -years (2009-2014 
 The language of the articles were in English 
 The articles are journal articles published in MEDLINE or CINAHL 
 The authority of the articles available from the internet are analysed in order to 
provide the validity 
 
The database search table presents the amount of articles found and selected accord-
ing to the databases. Articles found matching the keywords were recorded as hits. The 
number of articles remained after limitations mentioned earlier, are shown in column 
“limitations” in database search table. The headings and abstracts of these articles 
were read and if considered relevant and answering the study question, recorded as 
articles retrieved. Finally these articles were read through and if still regarded as suita-
ble, were noted as articles used. In total of 19 articles were chosen to this literature re-
view. The articles are listed in the database search table in appendix 2. 
 
5.4 Data analysis 
 
Content analysis is broadly used as an analysis method in health science. The purpose 
of the analysis is to conceptualise, summarise and generalise the phenomenon in order 
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to aid conclusion making. In a literature review content analysis can be used as a sup-
portive method. (Latvala & Vanhanen 2001:23; Kyngäs & Vanhanen 1999:3–4.) Content 
analysis is a qualitative method. Within qualitative research the phenomenon is exam-
ined holistically. A life is seen as a diverse phenomenon where different incidences affect 
each other’s. For that reason reality cannot be divided into different parts. In a qualitative 
method the approach is either inductive or deductive. The main difference between these 
methods, is how tentative codes and categories are formed. An inductive approach 
moves always from specific to general when deductive moves from general to specific. 
This final project follows the principles of the inductive content analysis method. (Cho & 
Lee 2014:4.) 
 
At the beginning of the process, the authors of this final project collected relevant data, 
which answered to the study question. The research process was initiated by reading 
and evaluating the material. After reading the material the authors analyzed and catego-
rized the data. Soon after the initiation of the analysis the authors of this final project 
acknowledged, that two major categories stood out from the findings: vaccination and 
screening. Sub-categories also rose up from these findings which include: knowledge, 
education, attitudes and beliefs, accessibility, feasibility, financial aspects, competing 
health needs, cultural aspects, infrastructural need and health care needs. The sub-cat-
egories did not directly answer the study question, but were closely related to the results. 
Sub-categories are included in the discussion. Categorisation was done in order to iden-
tify the key terms and to identify the sub-categories that formed the main factors influ-
encing prevention. A coding sheet is supplied in appendix 3 and an analysis of the arti-
cles in appendix 4.  
 
6 Findings 
 
The findings of this final project emphasise the importance of both primary and second-
ary prevention. The vaccinations have a great potential to reduce cervical cancer inci-
dence worldwide, however, screening programmes still remain as an important preven-
tion methods as current vaccines cannot provide total immunization for women. Accord-
ing to one study conducted in France vaccination along with the screening have a higher 
impact on reducing cervical cancer incidence than vaccination or screening alone (El 
Hasnaoui, Demarteau, Granados, Standaert & Detournay 2012:149).  
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6.1 Best practice for primary prevention 
 
Vaccination is profitable at any age, but the best results are gained when the vaccination 
is completed at the age of 11-13 years. (El Hasnaoui et al. 2012:149)  Almonte, Sasieni 
& Cuzick (2011:626) also highlight the importance of the vaccination at young age. Ac-
cording to Van Kriekinge et al. (2014:773) if 70% of young girls would be vaccinated in 
low- and middle- income countries, after 10 years, cervical cancer related death of four 
million women could be prevented. Cervical cancer mortality could be largely reduced 
by vaccinating young girls with bivalent vaccine (HPV 16, 18). In case; the vaccination 
would be performed with the quadrivalent vaccine (HPV 6, 11, 16, 18) the decrease of 
the mortality and incidence of cervical cancer would be 18% higher. (Van Kriekinge et 
al. 2014:773.) 
Kane (2012:27), Fu et al. (2014:1902) and Chan et al. (2012:481-486) state that immun-
isation programmes have a potential to achieve high coverage, when the price of the 
vaccine is reasonable and the vaccination programme is feasible to a country’s region 
and infrastructure. Van Kriekinge et al. (2014:733) claims that vaccination is a cost-ef-
fective primary prevention method in most of the countries, hence it saves money by 
decreasing the need of treatment interventions. Countries which have school based pro-
gramme have the highest vaccination rates worldwide. (Fu et al. 2014:1901) According 
to Binagwaho et al. (2012:625) high vaccination coverage is maintained most effectively 
when the vaccination is supported by the government. A good example of well a struc-
tured and planned vaccination programme comes from Rwanda. The country achieved 
remarkable improvement to vaccination coverage just in five years. The key to the suc-
cess in Rwanda was down to a well-planned delivery strategy and a human resource 
framework. The findings of the study suggest that for gaining most benefits, the vaccina-
tion program should be tailored to the countries special characteristics and needs. 
(Binagwaho et al. 2012:624-625.) Vaccination programmes have a great potential to re-
duce mortality and increase the life expectancy. Vaccination can subsequently promote 
the quality of life of the future generations. (Peate 2009:86.) Similarly, Almonte et al. 
(2011:626-627) states that the universal HPV vaccination for girls provides the best prob-
ability to control cervical cancer in future. After analyzing 72 countries with the highest 
prevalence of cervical cancer Fonseca, Ferreira and Neto (2013:448) also addressed 
that the vaccination would have a potential to significantly cut down the incidence and 
mortality of cervical cancer. Furthermore, their study found that, the effect was especially 
high in areas which did not have effective and well-structured screening programmes. 
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The results of the article by Monsonego, Cortes, Greppe, Hampl, Joura and Singer 
(2010:8070) and Kane (2012:24) noted that women with limited access to screening 
would benefit most from the vaccination. 
6.2 Best practice for secondary prevention 
 
Screening programmes should be performed worldwide, in order to lower the incidence 
of the cervical cancer and improving the early treatment rates (Hughes 2009:56). Screen-
ing programmes along with vaccination, are important firstly because vaccination cannot 
protect women who have had previous HPV infection; secondly, the vaccination pro-
grammes only cover certain age groups; and thirdly, because the vaccination can only 
protect women from cervical cancer that is caused by types 6, 11, 16 and 18. (Kim et al. 
2013: 60; Kling & Zeichner 2010: 377; Peate 2009:86; Teitelman et al 2009:69-73.) Re-
sults for this final project did not clearly state what is the best practice for the prevention 
of cervical cancer is globally however, certain methods were the most effective in specific 
regions. 
6.2.1 Cytology 
 
Cytology-based screening tests have been proven to be a successful prevention method 
that significantly reduces cervical cancer incidence and mortality in countries which have 
strong healthcare infrastructure and well established and sustained screening pro-
grammes (Almonte et al. 2011: 626-627; Denny 2012:189; Hughes 2009:56; Wright & 
Kuhn 2011:18, Sankaranarayanan, Nessa, Esmy & Dangou 2012:222). Liquid-based cy-
tology has replaced conventional cytology in many countries (Almonte et al. 2011:618). 
In 2011, more than 90% of Pap smears which were performed in the USA and UK were 
liquid-based (Denny 2012:193). Almonte et al. (2011:618) and Denny (2012:193) both 
emphasizes that even though the liquid-based cytology is a more expensive method than 
conventional cytology based screening, has great advantages; as it has lower rates of 
unsatisfactory smears and  more rapid interpretation compared to conventional cytology. 
Although cytology-based screening is simple in concept, it requires a functioning health 
care infrastructure which is able to provide consistent repetitive screening tests, referral 
for colposcopy, treatment of precursors, follow-up to detect failures of treatment, quality 
assurance and established registries. Since many middle- and low- income countries 
lack functioning health care infrastructure they face difficulties to maintain these require-
ments. (Wright et al. 2011:198; Denny 2012:189; Almonte et al. 2011:618). 
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6.2.2 Visual inspection with acetic acid 
 
Visual inspection with acetic acid (VIA) is used in  several developing countries as it 
needs minimal infrastructure, is affordable and gives immediate test results The disad-
vantages of VIA are subjective nature of the technique, low specificity and high false 
positivity as many women without lesions have acetowhitening of the cervix in areas of 
immature squamous metaplasia or reparative conditions. According to the article this 
inevitably leads to over-referral, over-treatment and unnecessary anxiety. (Sanka-
ranarayanan et al. 2012:226; Wright et al. 2011:200).Furthermore, Sankaranarayanan 
et al. (2012:226) claims that the low cost of VIA may be outweighed by the cost of over-
treatment and over-investigations. However, Kim et al. (2013:60-72), Sankaranarayanan 
et al. 2013:51 and Ardahan & Temel (2011:158) state that VIA is an effective option to 
reduce cervical cancer incidence and diminish the probability of mortality in low-resource 
countries. 
 
6.2.3 Human papillomavirus test 
 
Human papillomavirus testing (HPV) combined to appropriate treatment has been 
proven to decrease the incidence and the mortality of cervical cancer (Almonte et al. 
2011:627; Denny 2012:194; Wright et al. 2011:202). According to these articles, several 
studies (in Europe, US, India, China, Mexico, Vanuatu) present overwhelming evidence 
that HPV test screening is frequently more sensitive, but less specific than cytological 
screening and VIA for detecting pre-cancer. Another, advantage of HPV is that it provides 
a long-term protective effect when women test negative. (Wright et al. 2011:197-208; 
Almonte et al. 2011:619-620; Denny 2012:194.) Therefore,  Almonte et al. (2011:623) as 
well as Wright et al. (2011:197-208) emphasise that the intervals of testing could be 
prolonged. Along with this Almonte et al. (2011:626) states that women who are vac-
cinated at a young age would require only three HPV tests during their lifetime, and the 
cancer rate would be reduced by 90%.  
Women aged 30 or over are more likely to have persistent infection, when young 
women’s HPV infection generally heals spontaneously (Almonte et al. 2011:624-625). 
Therefore screening with a HPV test is suitable for women aged 30 and over. The current 
HPV test is costly, needs well-equipped laboratories and a “screen-and-treat” version is 
not yet available. However, a potential advantage of HPV testing over other screening 
methods is the possibility of self-collection of the test by vaginal swabs. In 2011, many 
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European countries began to change a cytology-based screenings to a HPV-based one 
either as an adjunct to cervical cytology or as a total replacement. (Wright et al. 
2011:197-208.) In the USA, the HPV test with cytology (co-test) is approved as a primary 
screening method and in Mexico is implemented as one (Almonte et al. 2011:619). Al-
monte et al. (2011:625) also clearly state that HPV test should be used in regions where 
the quality of screening cannot be maintained or where screenings do not exist.  
6.2.4 ‘Screen-and-treat’ 
 
Studies have shown that ‘screen-and-treat’- method prevents cervical cancer most ef-
fectively when screening is linked to treatment in a same visit without colposcopy. The 
advantages are the need of a single visit, treatment on time and it does not require a 
tracking and recall system for untreated women. Since, in this method women are treated 
without double checking the positive result and the specificity of tests varies, 5-20% of 
women will be treated unnecessary. (Wright et al. 2011:200-203; Sankaranarayanan et 
al. 2012:222.) Almonte et al. (2011:625) notes that VIA combined with cryotherapy has 
been a common ‘screen-and-treat’- approach in low-resource areas because it can be 
performed by a non-physician and is low-cost. If a HPV screening test is available and 
coupled with cryotherapy in screen-positive women, moderate and severe cervical dys-
plasia would be reduced about 72% (Wright et al. 2011:203). 
In conclusion cervical cancer is largely preventable when an adequate services and pre-
vention methods are available and they are realistic for the country´s infrastructure and 
health care resources. (Sankaranarayanan et al. 2013:51)  
7 Validity 
 
 
Validity is an essential tool in research to assess and interpret the quality of collected 
data and the study findings. Validity considers, whether the findings are convincing, well-
grounded and unbiased (Polit & Beck 2004:36). However, measuring the validity is chal-
lenging and the neutrality of findings is difficult to measure (Burns & Grove 2005: 383).  
 
Articles used in this final project were published in academic journals. In addition, the 
authority of the articles available from the internet are analysed in order to provide the 
validity. The articles from web-sites, such as Wikipedia.org with no known authors, were 
not used in the literature review. Data is considered valid when it is ensured that its 
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answers the study question and remains within the inclusion criteria (Trochim 2006). 
When assessing validity of a qualitative study, two strategies are recommended to use: 
internal and external criticism. By external criticism, a reader finds out why, where and 
how an empirical study is conducted then through an internal criticism bias of the author 
is evaluated and the results and the statements of the research are considered carefully. 
(Burns & Grove 2007:74-75.) These interventions were done to all chosen articles. The 
two authors of this final project separately considered and evaluated through internal and 
external criticism the validity of each chosen article. Before including an article to the 
literature review, both authors shared the same views and insight and considered it worth 
for the literature review. The chosen articles were gathered from around the world to 
provide a large scope for interpretation. The research findings were presented as they 
are in the articles to support conformability (Polit & Beck 2004:36). 
The Metropolia University of Applied Sciences guidelines for literature review were fol-
lowed throughout the final project process. This final project was given to instructors and 
presented on seminars regularly for follow-up. The suggestions for quality improvements 
were then followed. In addition, the quality of academic language was checked by an 
English teacher. 
Validity of the results can be affected by misunderstandings of translation, a reviewer’s 
subjective view on the topic and articles which reviewers choose to be included as most 
valid in this final project. As an objective view should be maintained through the research 
project (Tuomi & Sarajärvi 2009), researchers are aiming not to involve their own views, 
opinions or interpretations in the process. 
8 Ethical considerations 
 
The ethical awareness of sensibility is important to maintain all the way from the begin-
ning of the process until the end (Kjellström & Fidlund 2010:383). When performing an 
analysis process of the articles is essential to consider the accuracy of the researches 
(Burns & Grove 2003:430). A code of ethics, ethical review boards and governmental 
regulations are institutions that regulate ethical violations and misbehavior in research. 
To regulate ethical violations in research today many medical journals use ethical guide-
lines’ requirements approved by the ethical review boards. When performing a literature 
review it is important to check whether an article has any mentions of ethical considera-
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tions and if not, the ethical competency of an article should be considered carefully (Kjell-
ström & Fidlund 2010:384.) According to Kjellström and Fidlund (2010) inadequate re-
porting about the research ethics in a long period may harm the status and the role of 
the research in health care and society. (Kjellström & Fidlund 2010:391) To ensure the 
objectivity and accuracy of the research is recommended that an external person evalu-
ates the ethical legitimacy of the research and gives their opinion and guidance (Polit & 
Beck 2004: 159). 
 
Misconduct and fraud are two major ethical issues in a research.  Misconduct empha-
sizes an ignorance and carelessness during a research process, including inadequate 
referencing of previous findings, not giving credibility to other authors, inaccurate report-
ing of methods and research and publishing old results as a new. (Academy of Finland 
2003:22.) Scientific fraud is a serious ethical issue which includes intentional or uninten-
tional misleading of scientific communities. Scientific fraud includes fabrication, plagia-
rism, falsification and misappropriation. Fabrication occurs when false perceptions or re-
sults are conducted to the study or observations are made in a different manner or 
method than mentioned in a study. Falsification means that original references are mis-
conducted and a content is changed or the result of the research is selected or changed 
without any scientific argumentation. In addition, leaving out relevant conclusion for the 
results can be seen as falsification. Plagiarism is borrowing or copying someone else’s 
text without permission and giving credibility. Finally, misappropriation means stealing 
author's idea, plan or findings. (Academy of Finland 2003:7, 22.)  
 
The authors of this final project have acknowledged the risk of bias, fraud and miscon-
duct and are prevalent and these have been considered throughout the process. In ad-
dition, objective guidance from an external person was utilized. Personal opinions and 
interpretations were acknowledged and avoided by double checking of both authors. At 
the beginning of the process, an official contract with the school, committing to follow the 
ethical principles of the research. When performing the data analysis, it was checked if 
the article mentions the ethical consideration and limitations of the study. To avoid pla-
giarism, the results of the studies were paraphrased without misconducting or converting 
the statements of the original author. Finally the final project was run through the 
“Turnitin” programme which have been designed to reveal the plagiarism. The sources 
utilized in this literature review are accurately cited and all the references were listed 
according to Metropolia University of Applied Sciences Guidelines for Writing Papers. 
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9 Limitations of the literature review 
 
A literature review of prevention of cervical cancer is a vast area to cover thoroughly. 
Database searches gave huge amount of articles to cover in a limited time. As the au-
thors of this final project were student nurses who had no previous experience of re-
search or writing literature review, the lack of experience may have been affected on 
validity and consistency of the database search and analyzing process.  
To minimize the risks, the authors familiarized themselves with the literature review pro-
cess and carefully followed the principles of the literature review with a guidance of the 
school senior lecturer. 
10 Discussion 
 
The purpose of the final project was to describe evidence based knowledge of the pre-
vention of cervical cancer and to describe the best practices of the prevention of cervical 
cancer. Professional literature regarding the subject is vast, however, all the articles 
which were read to this literature review shared similar views and no disparities were 
found. Vaccination and screening were the two main themes. To be able to implement 
these effectively cervical cancer prevention requires sufficient infrastructure and financ-
ing, appropriate health education to increase knowledge and guarantee of access to 
preventive services. 
10.1 Screening as a primary prevention method 
 
The study findings did not clearly show which of the screening options is the most effec-
tive for the prevention of cervical cancer, as all three have their own advantages and 
disadvantages. However, findings note that certain types of screening are more suitable 
to certain regions. Thus, in reducing cervical cancer incidence and mortality in low-re-
source setting, the most suitable screening method may be VIA and in high-resource 
countries, cytology-based screenings (conventional and liquid-based) may be used as 
secondary prevention methods. Currently LBC offers advantages over conventional cy-
tology, after all both of them require complex infrastructure. In the future, a cytology-
based screening test might gradually change to HPV screening as the vast evidence 
favours its superiority. However, cytology or VIA can be used as a valuable triage to 
avoid an increase in the referral rates to colposcopy (Almonte et al. 2012:625). VIA might 
also be replaced by HPV test that are shown to be simple, rapid and suitable for ‘screen-
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and-treat’ HPV testing and will soon be available. According to study findings the ‘screen-
and-treat’-method seems to be appropriate approach especially to developing countries. 
Over-detection is a disadvantage of all screening tests which leads to overtreatment of 
women. Nevertheless, the benefit of detecting pre-cancerous lesions early outweighs the 
relatively small consequences of unnecessary treatments and above all more cervical 
cancer will be prevented than in the presence of non-existence of screenings (WHO 
2014:124). 
10.2 Vaccination as a secondary prevention method 
 
In 2006 the HPV vaccination was introduced, after which countries started to integrate it 
into their vaccination programmes. The findings of this final project clearly state that the 
vaccination is the best practice for primary prevention of HPV, since it is relatively cost-
effective and has potential to reach large number of girls. Vaccination programmes could 
provide a solution to low- and middle- income countries which have had difficulties to 
initiate and sustain screening programmes. In addition since most of the countries al-
ready have an existing vaccination programme, HPV vaccinations could be integrated 
into the existing vaccination programmes. Vaccinations are relatively common proce-
dures all over the world and it is generally highly accepted. Hence, it could be assumed 
that women and men would have less fears and misbeliefs as well as individual and 
cultural barriers against vaccination than screenings. However, as the vaccination nei-
ther provides 100% protection nor cures the already existing infection, screenings are 
still as a valuable prevention methods as vaccination. Thus, the results of this final project 
state that the most effective method to manage the cervical cancer prevention is to com-
bine screening and vaccination. 
 
10.3 Nurses role in prevention 
 
Poor knowledge of HPV and cervical cancer was stated as a major barrier to preven-
tion in several articles (Chan et al. 2012:481-482; Natunen et al. 2011; Tu & Wang 
2013:330; Kessler 2012;61). Nurses and other health care providers are in an es-
sential role in promoting sexual health and providing education (Boyce & Holmes 
2012:43416; Donati et al. 2012:2081; Gulhane, Akyuz & Yenen 2013:146-157; Teitel-
man et al. 2009:76; Wamai et al. 2013:1399-1406; Chan et al. 2012:485). From ed-
ucation, nurses are able to increase knowledge, and change attitudes and misbeliefs.  
22 
 
Current, accurate and relevant information for women, girls and men is valuable as it 
affects screening and vaccination attendance as well as reducing fears and concerns 
(Chan et al. 2012:484-485; Tu & Wang 2013:330). Education should be targeted mostly 
at women and girls however, as a woman’s risk of being infected of HPV does not de-
pend only on her own sexual behavior but also on her partner’s behaviour, educating 
males about HPV infection would also be beneficial. Additionally, because attendance to 
programmes is partly dependent on attitudes of parents, spouses, relatives, politicians 
or other influential people of community (Natunen et al. 2011), education should be pro-
vided to them as well. 
Studies have shown that health care professional’s attitudes and knowledge of the pre-
ventive services influence on uptake rates (Fonseca et al. 2013:448;  Chan et al. 
2012:485; Peate 2009:86-89). Therefore, an adequate training and education concern-
ing HPV and cervical cancer should be provided for nurses and health-care providers so 
that they are able to educate people appropriately. Nurse should acknowledge that can-
cer and sexually transmitted infections may be associated with fears, misconceptions or 
stigma. In order to overcome these issues and building a trust with patient, a nurse 
should be able to respond accurately and share information in a respectful and sensitive 
manner. 
 
10.4 Factors affecting prevention 
 
There are several other factors, which influence cervical cancer prevention as noted 
in reviewed literature. We will discuss briefly of the barriers, school-based vaccina-
tion, media’s role and the impact of male vaccination. 
 
10.4.1 Barriers 
 
According to findings of this study cervical cancer prevention services are best organized 
in areas with well-structured infrastructure and functioning health care services. Areas 
with poor infrastructure, low income and low acceptance are struggling in providing cer-
vical cancer services. Enabling women's access to preventative health care and provid-
ing education is crucial to decrease the incidence of cervical cancer. According to our 
findings, prevention strategies are most effective when they are adjusted to regional and 
cultural needs. The preventative methods used should be tailored for local practice and 
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women's needs. Thus, in order to maintain a well-established prevention program ethi-
cal, cultural, social and practical factors must be acknowledged. Furthermore, Natunen 
et al. (2011) emphasises that adjusting prevention strategies to local needs would im-
prove the feasibility and increase the access, coverage and acceptability. When consid-
ering the local needs several issues needs to be taken into account, such as: the lan-
guage used, the readability, structural format and the content of the educational material. 
Ideally, the educational material should meet women’s/men’s ages, status’, educational 
levels, cultural/ethical backgrounds and beliefs and misconceptions. (Maree & 
Wright 2011:118–122.) 
 
10.4.2 School- based vaccination program 
 
Our findings suggest that the vaccination and screening are most effective when funded 
by government. Thus, governments should be encouraged to include a HPV vaccine into 
an immunisation program and support regular screenings. (Perkins, Langrish, Cotton & 
Simon 2011:85-90; Kwan et al. 2011:118-122.) Furthermore, our findings demonstrate 
that countries which have school-based vaccination programmes generally have the best 
coverage and compliance of HPV vaccination (Kane 2012:26; Natunen et al. 2011). Also, 
the health education of HPV could easily be related to a school’s sexual education pro-
gram, which would increase the knowledge of preventative services and methods. 
School vaccination would be profitable since our finding states that the best age to vac-
cinate is at an age of 11-13. However, since girls are under-aged when vaccinated pa-
rental approval is required. By providing information to parents, school nurses ensure 
that the parents have adequate knowledge and are able to make informed decisions. In 
order to diminish the fears and doubts of the parents, it is essential that school nurses 
are well educated and able to utilize and cite evidence-based knowledge as a basis of 
education. (Kwan et al. 2011:118-122; Lockwood-Rayermann & McIntyre 261-268; 
Teitelman et al. 2009:69-76.) Some parents express that vaccinating young girls will im-
ply risky sexual behaviour (Lockwood-Rayermann & McIntyre 2009:267; Chan et al. 
2012:485). The information shared about HPV vaccinations would be more profitable if 
it focuses more on self-protection than sexual behaviour and STD’s, since this would 
ease the concerns about vaccination causing adolescent promiscuity (Maree & Wright 
2011:122; Kwan et al. 2011:118-122; Markovitz, Song, Paustian & Reda 2014:34). This 
would apply to both schools and in general. Maree and Wright (2011:118-123) noted that 
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education material highlighting sexual behavior, multiple partners and sexually transmit-
ted disease has been linked to promiscuity, stigma and labeled women as a “bad 
women”. This is especially seen in cultures where attendance to vaccination and gyne-
cologic exams before marriage can be related to unaccepted premarital sexual behavior 
(Ersin & Bahar 2013:4977-4829; Gu, Chan & Twinn 2010:445-453). Stigma was shown 
to be a powerful barrier to vaccination, screening and treatment therefore nurses should 
present information in a culturally competent and non-stigmatising way. 
 
10.4.3 Quadrivalent vaccination for males 
 
Quadrivalent vaccines protect from type 11, 6, 16, 18 HPV strands, when bivalent pro-
tects only from types 16 and 18. Types 11 and 6 are responsible for most of the genital 
warts and condylomas (WHO 2014:99; SALC 2012:10.) Quadrivalent HPV vaccination 
is also available for males with the potential to reduce HPV transmission, genital warts, 
oral, anal and penile cancer. As the incidence of HPV related non-cervical cancer is 
relatively low and the high coverage of female-only vaccination have potential to reduce 
HPV incidence markedly. Since the incidence of other HPV-related cancers at such a 
low in this sense vaccinating males is not cost-effective. (Kim et al. 2013:60-72.) Alt-
hough Peate (2009:89) states that if the vaccination would also cover males, the mass 
immunity effect would be greater which would decrease the chance of the transmission. 
Similarly, the result of this study suggest that cervical cancer mortality and incidence 
could be reduced by 18%, if the vaccination used would be quadrivalent instead of biva-
lent. According to this theory a vaccinated male would prevent a female from getting 
HPV-infection. However, the benefits of cervical cancer prevention by male vaccination 
is still unclear. Further studies are needed (Lockwood-Rayermann & McIntyre 2009:261-
269). 
10.4.4 Strategies to improve attendance 
 
As mentioned before knowledge and attitudes have a major influence on people’s cervi-
cal cancer prevention attendance. In order to change attitudes and awareness is im-
portant to increase people’s level of knowledge of the disease. These days, media has 
an important role as an information channel and it can affect highly on attitudes. Accord-
ing to studies, positive media attention can increase uptake and acceptance of the vac-
cine and screening programmes. (Hilton, Kunt, Langan, Bedford & Petticrew 2010:942-
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950.) Thus, in order to maintain better cervical cancer prevention attendance rates edu-
cational interventions and media campaigns should be used. 
Several countries have used different approaches to increase the level of knowledge and 
use of preventive services. In Zambia, traditional marriage counselors have been edu-
cating women and their families about cervical cancer (Kapambwe, Parham, Mwa-
nahamuntu, Chirwa, Mwanza & Amuyunzu-Nyamongo 2013:57-64). In South Korea in-
creased cervical cancer awareness has come from several campaigns on TV, radio, 
buses, the subway and, social media. As a result of these campaigns screening rates 
were duplicated and vaccination rates were significantly increased. (Perspectives in Pub-
lic Health 2013.) Gulhane, Akyuz and Yenen’s research in Turkey (2013) demostrated 
that educational brochures were effective in providing information to large number of 
women who have little or no knowledge of cervical cancer.  
 
10.5 Suggestions 
 
 
Based on the findings and all the articles read, some suggestion can be made. Edu-
cation concerning HPV and cervical cancer could be added to public education of 
women’s health worldwide as it has been stated that through better knowledge peo-
ple are empowered to make more consensual health decisions (Hunter & Kelly 2012). 
As stated before education should be provided to vast range of people. Additionally 
health providers should be adequately trained and national guidelines provided. 
Since preventive services are effective only when they are accessible, strategies 
should be developed to guarantee women’s access. This should not be dependent 
on distance to facilities, women’s social or economic status or local culture.  Espe-
cially, low- and middle income countries’ health care systems should be strength-
ened to make preventive services feasible and affordable.  
 
11 Conclusion 
 
As noted earlier cervical cancer is generally a well preventable and treatable cancer. The 
incidence of cervical cancer has reduced significantly in developed countries as a result 
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of well-established screening and treatment programmes. However, cervical cancer con-
tinues to be one of the most common cancers affecting women in developing countries, 
causing high mortality. Approximately, 85% of all cervical cancer cases occur in devel-
oping countries. Global disparities are mainly caused by shortage of prevention services, 
accessibility, lack of knowledge and the high incidence of competing health needs. 
(Wright et al. 2011; Saraiya, Steben, Watson & Markowitz 2013:426-33.)  
 
The findings of this project suggest that the most effective prevention strategy is to com-
bine vaccination with well-organized national screening program. Vaccination has a po-
tential to reduce significantly HPV infections, as it can achieve high coverage and ac-
ceptance levels. However, screening programmes remain valuable prevention method 
as vaccination cannot protect women from all HPV infections. Hence, people generally 
have poor knowledge of HPV infection and it’s relation to cervical cancer, nurses play an 
important role in providing education and promoting sexual health. Increased knowledge 
positively correlates with screening and vaccination attendance, as it decreases fears 
and misbeliefs. In many countries cultural, ethical, social, infrastructural or/and practical 
barriers exist. In order to maintain an effective cervical cancer prevention it is essential 
to acknowledge the existing barriers of the region. Nurses should be trained to provide 
health education that is tailored for to a local cultures and needs. Education should be 
targeted to women and girls who are eligible for preventative services as well as to their 
family members and authorities who might have influence on their vaccination and 
screening behavior. Nurses can ensure that women, families and communities under-
stand that cervical cancer is preventable and curable (WHO 2014:5). 
 
As more research is continually done and new approaches are developed for both pri-
mary and secondary prevention, recommendations and best practices are likely to 
change in the near future (Almonte et al. 2011). These have the potential to confront 
cervical cancer in a more comprehensive way and make a healthier future for girls and 
women.  
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prevention+ vaccination 
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 Meaning Unit Condensed Mean-
ing Unit 
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Article 1 
Chan, Z., Chan, T., Ng, K. and 
Wong, M.(2012). A Systematic 
Review of Literature about Wom-
en's Knowledge and Attitudes To-
ward Human Papillomavirus 
(HPV) Vaccination. Public Health 
Nursing  29 (6), 481-489 
“Factors affecting women’s ac-
ceptance of HPV vaccination in-
clude knowledge, safety, cost and 
the efficacy of the vaccine.” 
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safety, cost and 
efficacy affect the 
acceptance of the 
vaccine 
Acceptance, 
knowledge, safety, cost, 
efficacy 
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Kim, J., Campos, N., O`Shea, M., 
Diaz, M., and Mutyaba,I. (2013). 
Model-Based Impact and Cost-Ef-
fectiveness of Cervical Cancer 
Prevention in Sub-Saharan Africa. 
Vaccine 31 (5), 60-72 
HPV DNA testing and visual in-
spection of the cervix using acetic 
acid (VIA), have been demon-
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HPV DNA testing 
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tive and potentially 
cost effective in 
low resource 
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HPV-testing, VIA, effec-
tive, cost-effective 
 Assuming 70% vaccination cover-
age, over 670,000 cervical cancer 
cases would be prevented among 
women in five consecutive birth 
cohorts vaccinated as young ado-
lescents; over 90% of cases 
averted were projected to occur in 
countries eligible for GAVI Alli-
ance support 
High vaccination 
coverage would 
reduce signifi-
cantly cervical 
cancer cases, es-
pecially in GAVI 
eligible countries 
Vaccination, High cov-
erage, cervical cancer, 
GAVI 
Article 3 
Kling, M. and Zeichner, J. (2011) 
The Role of the Human Papillo-
mavirus (HPV) Vaccine in Devel-
oping Countries. International 
An HPV vaccine program in un-
derdeveloped nations would re-
duce the spread of HPV 16 and 
18, and thereby significantly lower 
the incidence of the associated 
cervical cancer.  
HPV vaccination 
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significantly re-
duce the cervical 
HPV vaccination, cervi-
cal cancer, developing 
countries, incidence 
Appendix 2 
2 (4) 
 
 
Journal of Dermatology 49 (4), 
377-379 
cancer inci-
dence  in develop-
ing countries 
Article 4 
Peate, I. (2009) The Introduction 
of the Human Papillomavirus Vac-
cine - Key Issues. British Journal 
of Nursing 18 (2), 86-89 
It takes many years for cervical 
cancer to develop following HPV 
infection. Therefore, it will take 
many years before the introduc-
tion of a vaccine has any major ef-
fect on the number of cases of 
cervical cancer. It is vital in the in-
terim that women continue to be 
screened for cervical cancer risk. 
cervical cancer de-
velop slowly, 
hence the effect of 
vaccination intro-
duction is slow, 
therefore is vital 
for women to con-
tinue to be 
screened 
cervical cancer, scree-
ning, vaccination 
 Vaccines are responsible for an 
increase in life expectancy and 
quality of life – the HPV vaccine 
and its introduction is likely to con-
tribute to a significant increase in 
life expectancy as well as quality 
of life for future generations.  
HPV vaccination 
can increase the 
life expectancy 
and quality of life 
HPV vaccination, qual-
ity of life, life expec-
tancy 
Article 5 
Teitelman, A., Stringer, M., Aver-
butch, T. and Witkoski, A. (2009). 
Human Papillomavirus, Current 
Vaccines, and Cervical Cancer 
Prevention. Journal of Obstetric, 
Gynecologic & Neonatal Nursing 
38 (1), 69-80 
The new human papillomavirus 
vaccine advances cervical cancer 
prevention; however, provider-rec-
ommended screening with Papan-
icolaou tests and lifestyle modifi-
cations are still needed 
 
Vaccine ad-
vantage cc pre-
vention, however 
pap-test and life-
style modifications 
are needed 
vaccine, prevention, 
cervical cancer, pap-
test, lifestyle 
 The currently approved vaccine 
does not provide immunity to all 
strains of HPV. Therefore, reduc-
ing the risk of 
exposure to the virus as well as 
other STIs remains 
an important component of pre-
vention. Also, wo- 
Vaccination does 
not provide full 
protection against 
HPV infection, 
therefore is im-
portant women to 
reduce to risk of 
Vaccination, protection, 
risk of exposure, 
screening 
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men still need to receive regular 
Pap tests and 
subsequent follow-up care for ab-
normal results in 
order to promote e arly detection 
and treatment of 
cervical cancer. 
exposure and un-
dergo regular 
screening and fol-
low up 
 Currently, the HPV vaccine is not 
recommended for 
older women 
HPV vaccine is not 
recommended for 
older women 
HPV vaccine, recom-
mendation, older 
women 
Article 6 
El Hasnaoui, A., Demarteau, N., 
Granados, D., Standaert, B and 
Detournay, B. (2012). Public 
Health Impact of Human Papillo-
mavirus Vaccination on Preven-
tion of Cervical Cancer in France. 
International Journal of Public 
Health 57 (1), 149-158 
Vaccination was beneficial regard-
less of the age, but the clinical re-
sults were the best for vaccination 
at 11-13 years when lifetime hori-
zon was considered, and for vac-
cination at 15-17 years for shorter 
observation period. 
The clinical results 
were the  best for 
vaccination at 
ages 11-13 years 
old. 
Vaccination, effective, 
11-13 years old 
 Vaccination combined with 
screening substantially reduced 
the incidence of precancerous le-
sions and CC compared with 
screening alone.  
Vaccination com-
bined with screen-
ing reduced more 
cervical cancer 
cases than 
screening alone 
Vaccination, screening, 
cervical cancer 
Article 7 
Fonseca, A., Ferreira, L. and 
Neto, G.(2013).Cost-effectiveness 
of the vaccine against human 
papillomavirus in the Brazilian 
Amazon region. Revista Da Asso-
ciacao Medica Brasileira  59 (5), 
442-451 
The analysis also showed the fa-
vorable cost-effectiveness profile 
of the vaccine in regions where 
CC was not controlled by conven-
tional screening programs. Con-
versely, in developed countries 
that succeeded in controlling CC 
incidence and CC-related mortal-
ity with solid gynecological 
screening programs, the HPV 
Vaccine were 
cost-effective in 
regions not con-
trolled by conven-
tional screening 
programs. 
Vaccine, cost effective-
ness, screening pro-
gram 
Appendix 2 
2 (4) 
 
 
vaccine is not as favorable from a 
cost-effectiveness standpoint (Ire-
land,UK, Switzerland, and Fin-
land. 
Article 8 
Monsonego J., Cortes., Greppe., 
Hampl., Joura, E and Singer, A. 
(2010). Benefits of Vaccinating 
Young Adult Women With a 
Prophylactic Quadrivalent Human 
Papillomavirus (types 6, 11, 16 
and 18) Vaccine. Vaccine 28 (51), 
8065-8072 
Finally, from an ethical perspec-
tive, women with poor access to 
screening or low compliance 
could potentially get even more 
benefit from vaccination.  
women with poor 
access to screen-
ing or low compli-
ance could benefit 
from vaccination 
access, screening 
vaccination 
Article 9 
Kane, M. (2012)Preventing Can-
cer with Vaccines: Progress in the 
Global Control of Cancer.     Can-
cer Prevention Research; 5(1) 24-
29  
Immunization is even more im-
portant in countries with poor 
screening programs because 
even the poorest developing 
countries generally do well at im-
munizing children 
Immunization is 
more important in 
countries with poor 
screening pro-
grams 
Immunization, scree-
ning  
 Inclusion of HPV vaccine in na-
tional immunization programs is 
not just a financial issue but will 
require changes in vaccine deliv-
ery infrastructure.         
Inclusion of HPV 
vaccine requires 
changes in vac-
cine delivery and 
infrastructure 
HPV vaccine, infrastruc-
ture, delivery 
Article 10 
Van Kriekinge, G., Castellsague, 
X., Cibula, D. and Demarteau, N. 
(2014). Estimation of the  
potential overall impact of human 
papillomavirus vaccination on cer-
vical cancer cases and 
deaths.Vaccine 32 (6), 733-739 
HPV-16/18 vaccine could reduce 
the number of CC cases and 
deaths in countries worldwide, 
with associated cost-offsets due 
to reduced CC treatment.  
When protection of more than two 
HPV types was considered, the 
number of CC cases and deaths 
potentially prevented by vaccina-
tion was at least 18% larger. 
HPV-16/18 vac-
cine can reduce 
the cost-offsets 
due to reduced cc 
treatment. 
Protection more 
than two types can 
prevent 18% more 
cases 
Vaccine, cost-offsets, 
cervical cancer treat-
ment 
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Article 11 
Almonte, M., Sasieni, P. and Cuz-
ick J. (2011). Incorporating Hu-
man Papillomavirus Testing into 
Cytological Screening in the Era 
of Prophylactic Vaccines. Best 
Practice & Research in Clinical 
Obstetrics & Gynaecology 25(5), 
617-629 
Women vaccinated at ages 11–14 
years could almost certainly have 
greatly reduced screening. 
 
Vaccination at age 
11-14 years old 
will reduce screen-
ing. 
Vaccination, ages 11-
14. 
 Cytology screening has been suc-
cessful in countries with organised 
screening programmes and in 
those with high-coverage oppor-
tunistic screening. 
Cytology-based 
screening has 
been successful in 
countries with or-
ganised screening 
programmes and 
with high-cover-
age. 
CBS, successful, organ-
ised screening program, 
high-coverage 
 LBC has advantages (rapid inter-
pretation, lower rate of unsatisfac-
tory smears, and the possibility of 
ancillary molecular testing using 
remnant fluid) but it is more ex-
pensive (per sample). 
LBC has ad-
vantages; rapid in-
terpretation, lower 
rate of unsatisfac-
tory smears and 
the possibility of 
ancillary molecular 
testing but it is ex-
pensive. 
LBC, rapid interpreta-
tion, lower rate of unsat-
isfactory smears, more 
expensive 
 LBC has replaced conventional 
cytology in several countries. 
LBC is used in 
several countries. 
LBC, several countries 
 It (CBS) has had no major effect, 
however, on reducing incidence 
and mortality rates in the develop-
ing world where appropriate re-
sources and infrastructure are not 
available or difficult to maintain. 
CBS hasn’t re-
ally  reduced inci-
dence or mortality 
in the developing 
world where ap-
propriate re-
CBS, developing world, 
not effective 
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sources and infra-
structure are not 
available main-
tained. 
 There is increasing evidence that 
HPV testing results in a subse-
quent decrease in incidence of 
and morbidity from cervical can-
cer. 
HPV testing de-
crease incidence 
of and morbidity 
from cervical can-
cer. 
HPV test, incidnece, 
mortality 
 HPV testing, however, is being 
used for primary screening nation-
ally in Mexico,and it is approved 
to be used in combination with cy-
tology (co-testing) in primary 
screening in the USA 
HPV testing is pri-
mary screening in 
Mexico and it is 
approved in com-
bination with cytol-
ogy (co-testing) in 
the USA 
HPV test, primary 
screening test 
 The overwhelming evidence from 
cross-sectional studies, longitudi-
nal studies and randomised clini-
cal trials show that screening with 
HPV testing is substantially more 
sensitive but less specific than cy-
tological screening and VIA for 
detecting high-grade CIN.  
Screening with 
HPV testing is 
more sensitive but 
less specific than 
cytological screen-
ing and VIA for de-
tecting high-grade 
CIN.  
HPV test, sensitive, less 
specific 
 Several studies have shown that a 
woman who tests negative for 
HPV has a low risk of developing 
cervical disease for at least 6 
years.  
Woman who tests 
negative for HPV 
has a low risk of 
developing cervi-
cal disease for at 
least 6 years.  
HPV test, 6years  
 Women aged 30–35 years or 
older, who test positive for HPV, 
are more likely to have persistent 
HPV testing 
should currently 
not start before 
age 30 years. 
HPV test, 30 years 
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infections that require further eval-
uation and follow up, thus, HPV 
testing should currently not start 
before age 30 years. 
 Screening with HPV testing just 
three times over a lifetime at ages 
30, 40 and 55 years (in vac-
cinated women) would reduce the 
risk of cervical cancer by over 
90%. 
HPV testing three 
times over a life-
time at ages 30, 
40 and 55 years 
(in vaccinated 
women) would re-
duce the risk of 
cervical cancer by 
over 90%. 
HPV test, ages 30, 40, 
55 year, reduce the risk 
of cervical cancer 
 Women vaccinated against HPV 
16 and 18 could be safely 
screened at greatly extended in-
tervals. 
Vaccinated 
women could be 
screened at 
greatly extended 
intervals. 
Vaccination, extended 
intervals 
 The implementation of universal 
HPV vaccination of adolescent 
girls is the best prospect to control 
cervical cancer  
The universal HPV 
vaccination of girls 
is the best pro-
spect to control 
cervical cancer. 
HPV vaccination, uni-
versal 
 It is clear that HPV testing should 
be used in places where no 
screening is available or where 
the quality of cytology cannot be 
guaranteed.  
HPV testing 
should be used if 
screening isn’t 
available or the 
quality of cytology 
isn’t guaranteed.  
HPV test, places with-
out screening, quality 
Article 12 
Fu, L.,  Bonhomme, L.,  Cooper, 
S.,  Joseph, J. and  Zimet 
G.(2014). Educational interven-
tions to increase HPV vaccination 
Studies have found that individu-
als' knowledge and attitudes to-
ward the vaccine are associated 
with immunization uptake.  
 
Individual 
knowledge and at-
titudes impact on 
immunization up-
take. 
knowledge, attitudes, 
immunization 
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acceptance: a systematic review. 
Vaccine 32 (17), 1901-1920 
Overall, countries that have 
school-based vaccination pro-
grams, such as Australia, Great 
Britain and Portugal, have 
achieved the highest (80% or 
greater) female vaccination cover-
age rates  
 
Countries that 
have school-based 
vaccination pro-
grams have 
achieved the high-
est vaccination 
coverage rates. 
School-based vaccina-
tion, high coverage 
 Overall, countries that have 
school-based vaccination pro-
grams, such as Australia, Great 
Britain and Portugal, have 
achieved the highest (80% or 
greater) female vaccination cover-
age rates though Denmark has 
reached very high vaccination 
rates  
Countries with 
school-based vac-
cination programs 
have achieved 
highest vaccina-
tion coverage 
School-based, 
vaccination, coverage 
Article 13 
Binagwaho, A., Wagner, C., 
Gatera, M,  Karema, C.,  Nutt, C 
and  Ngabo, F. (2012). Achieving 
High Coverage in Rwanda’s Na-
tional Human Papillomavirus Vac-
cination Programme. Bulletin of 
the  World Health Organ 90 (80), 
623–628  
High coverage rates were 
achieved due to a delivery strat-
egy that built on Rwanda’s strong 
vaccination system and human re-
sources framework.  
Implementation must be tailored 
to the local context.   
High coverage 
rates were 
achieved due to a 
delivery strategy 
and human re-
sources frame-
work.  
Implementation 
have to be suitable 
to the local con-
text.  
High coverage rates, 
delivery strategy and 
human resources 
framework.  
Implementation, local 
context.  
Article 14 
Sankaranarayanan, R., Anorlu, 
R., Sangwa-Lugoma, G and 
Denny, L. (2013). Infrastructure 
Requirements for Human Papillo-
mavirus Vaccination and Cervical 
Cancer Screening in Sub-Saharan 
Africa. Vaccine 31 (5), 47-52 
VIA is particularly suitable to low-
resource settings; however, its ef-
ficacy in reducing cervical cancer 
is likely to be significantly lower 
than HPV testing. 
 
VIA is suitable to 
low-resource set-
tings. HPV testing 
will be even more 
effective. 
 
Cervical cancer 
can be prevented 
VIA, low-resource set-
tings 
HPV test, more effec-
tive, low-resource set-
tings 
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Research and experience show 
that cervical cancer can be pre-
vented when strategies and ser-
vices are provided in the context 
of adequate infrastructure and 
well-trained human resources and 
when attention is paid to pro-
gramme monitoring and evalua-
tion. 
when strategies 
and services are 
provided in the 
context of infra-
structure and 
trained human re-
sources and when 
programme moni-
toring and evalua-
tion is valued. 
Strategies, services, in-
frastructure, human re-
source, monitoring 
Article 15 
Hughes, C. (2009) Cervical can-
cer: prevention, diagnosis, treat-
ment and nursing care. Review. 
Nursing Standard. 23(27):48-56 
Cervical screening has signifi-
cantly reduced the number of 
women who develop or die from 
the disease but only in countries 
where there is easy access to cer-
vical cytology or an organised cer-
vical screening programme 
Cervical screening 
has significantly 
reduced the inci-
dence and mortal-
ity in countries 
where there is 
easy access to 
cervical cytology 
or an organised 
cervical screening 
programme 
Screening, effective, 
easy access, organised 
programme 
 Cervical screening programmes 
should be implemented worldwide 
to improve the detection of 
women at risk of developing cervi-
cal cancer and promote early 
treatment of the disease. How-
ever, in countries where this is un-
likely to happen, HPV vaccination 
may offer a solution for the future  
Screening pro-
gram should be 
implemented 
worldwide to re-
duce incidence of 
cervical cancer. 
Vaccination may 
be an option. 
Screening, worldwide. 
Vaccination, future 
Article 16 
Denny, L. (2012) Cytological 
screening for cervical cancer pre-
vention. Best Practice & Research 
in Clinical Obstetrics & Gynaeco-
logy. 26(2):189-96. 
Historically, the incidence and 
mortality of cervical cancer has 
declined in countries that have in-
stituted and sustained mass-or-
ganised cytology-based screening 
programmes.  
Incidence and 
mortality of cervi-
cal cancer is de-
clined in countries 
that have effective 
cytology-based 
Cytology- based 
screening, effective, 
countries with pro-
grammes 
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screening pro-
grammes 
 Liquid-based cytology currently 
accounts for more than 90% of 
Pap smears carried out in the 
USA and UK (is widely used 
throughout the developed) 
LBC is most used 
in USA and UK 
(developed coun-
tries) 
LBC, the most used, 
developed countries 
 
 LBC is reported to have a number 
of advantage: more representative 
transfer of cells; reduction in the 
number of unsatisfactory cells; 
higher detection rates of cellular 
abnormalities; availability for mo-
lecular testing; reduction of 
screening time and greater ease 
of screening; and possibility for 
automated interpretation. 
LBC has many ad-
vantages 
LBC, advantages 
 (CBS) also require a functioning 
healthcare infrastructure, with la-
boratories for smear processing 
and interpretation, mechanisms 
for quality control, referral for col-
poscopy, treatment of precursors, 
and follow-up to detect failures of 
treatment. Although this approach 
has been successful in preventing 
cervical cancer where imple-
mented correctly, it has proved in-
ordinately complex and expensive 
for developing countries.  
CBS require a 
functioning 
healthcare infra-
structure. 
Approach has 
been successful in 
preventing cervical 
cancer where im-
plemented cor-
rectly but has 
been complex and 
expensive for de-
veloping countries  
CBS, succesfull, comp-
lex, expensive 
 HPV testing has been subjected 
to numerous clinical trials and has 
been shown to be superior in sen-
sitivity to cytology, although less 
specific.  
HPV testing has 
been shown to be 
superior in sensi-
tivity to cytology, 
HPV test superior 
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although less spe-
cific.  
 Large randomised-controlled trials 
have shown significantly improved 
detection of cervical cancer pre-
cursors and reduction in cervical 
cancer in women tested with HPV 
and treated appropriately.  
Women tested 
with HPV and 
treated appropri-
ately have signifi-
cantly improved 
detection of cervi-
cal cancer precur-
sors and reduction 
in cervical cancer. 
HPV, appropriately 
treatment 
Article 17 
Wright TC Jr and Kuhn L (2011). 
Alternative approaches to cervical 
cancer screening for developing 
countries. Best Practice & Re-
search in Clinical Obstetrics & Gy-
naecology. 26(2):197-208 
Cytology as a screening test, 
linked with a robust healthcare in-
frastructure, has significantly af-
fected cervical cancer prevention 
in countries that have had suffi-
cient resources to establish and 
sustain well-conducted pro-
grammes.  
Cytology has sig-
nificantly affected 
cervical cancer 
prevention in 
countries that 
have well-con-
ducted and sus-
tained pro-
grammes.  
Cytology, countries with 
programmes 
 It has also been clearly shown 
that linking testing or screening to 
treatment (so-called ‘screen and 
treat’) without the intervention of 
colposcopy or the need for so-
phisticated laboratories may po-
tentially prevent cervical cancer in 
large numbers of women. 
‘Screen and treat’ 
may potentially 
prevent cervical 
cancer in large 
numbers of 
women. 
‘Screen-and-treat’, po-
tentially effective  
 Although simple in concept, cytol-
ogy-based prevention pro-
grammes have proven extremely 
difficult to implement in low-re-
source settings. 
Cytology-based 
prevention pro-
grammes are sim-
ple but difficult to 
implement in low-
resource settings. 
CBS, simple, complex 
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 Visual inspection with acetic acid 
is the simplest, and the low unit 
cost and the cost of the test itself 
makes it the least inexpensive 
screening test.  
VIA is the simplest 
and the least inex-
pensive screening 
test 
VIA, simple, low-cost 
 Many women without CIN 2 and 3 
lesions have acetowhitening of 
the cervix owing to areas of imma-
ture squamous metaplasia or re-
parative conditions. This can lead 
to a considerable degree of over-
referral and over-treatment of 
women who do not have CIN2+ 
lesions 
Many women with-
out CIN 2 and 3 le-
sions have 
acetowhitening of 
the cervix leading 
to a considerable 
over-referral and 
over-treatment. 
over-referral and over-
treatment (VIA) 
 Although it is difficult to know what 
the real performance will be of 
VIA when used in a developing 
country screening programme, 
considerable evidence currently 
shows that VIA should be consid-
ered as a reasonable alternative 
to cervical cytology. 
Considerable evi-
dence currently 
shows that VIA 
should be consid-
ered as a reasona-
ble alternative to 
cervical cytology in 
developing coun-
tries. 
VIA, alternative to cervi-
cal cytology, developing 
countries 
 Multiple studies have convincingly 
shown that hrHPV testing is more 
sensitive and more reproducible 
than cervical cytology. Moreover, 
because of the high negative pre-
dictive value of hrHPV testing, 
women who are hrHPV negative 
do not need to be rescreened be-
fore 6 years. 
HPV testing is 
more sensitive and 
more reproducible 
than cervical cytol-
ogy.  
HPV testing has 
high negative pre-
dictive, thus HPV 
negative women 
can be rescreened 
in 6 year interval 
HPV test, sensitive, re-
producible 
high negative predictive 
value, screening inter-
val 6years 
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 Currently, several European coun-
tries are beginning to transition 
from a cytology-based screening 
programme to a hrHPV-based 
one. A potential advantage of 
hrHPV testing over other screen-
ing methods for developing coun-
tries is that testing can be done on 
self-collected vaginal swabs. 
Many European 
countries begin to 
replace cytology- 
based screening 
to a HPV-based 
one. HPV testing 
can be done on 
self-collected vagi-
nal swabs. 
HPV, European count-
ries 
Self-collected 
 
 The greatest issues in hrHPV test-
ing for developing countries are 
the unit cost of the test, the so-
phistication of the laboratories that 
are needed for carrying out cur-
rent versions of the test, and the 
fact that a point-of-care hrHPV 
test is not yet available 
The issues in HPV 
testing for devel-
oping countries 
are the cost, the 
need of sophistica-
tion laboratories 
and that a point-of-
care HPV test is 
not yet available 
HPV, cost, laboratories, 
no point-of-care test, 
developing countries 
 The major disadvantage of 
‘screen-and-treat’ is that, depend-
ing on the specificity of the 
screening test, 5–20% of all 
women without CIN 2 and 3 le-
sions will undergo unnecessary 
treatment. 
Disadvantage of 
‘screen-and-treat’ 
is that, 5–20% of 
all women without 
CIN 2 and 3 le-
sions will undergo 
unnecessary treat-
ment. 
‘screen-and-treat’, un-
necessary treatment 
 Another advantage of ‘screen-
and-treat’ is that, if a point-of-care 
screening test is used, the entire 
process can be completed in a 
single visit and there is no need to 
establish a track and recall sys-
tem for patients. 
‘Screen-and-treat’ 
process can be 
done in a single 
visit and there is 
no need to estab-
lish a track and re-
call system for pa-
tients. 
‘Screen-and-treat’, sin-
gle visit, no track and 
recall system 
Appendix 2 
2 (4) 
 
 
 if a highly sensitive screening test 
such as hrHPV testing is used 
that has a sensitivity of 90% for 
CIN 2 and 3 lesions, and this test 
is coupled with cryotherapy to ab-
late the transformation zone in all 
screen-positive women (which 
eliminates about 80% of CIN 2 
and 3 lesions), the overall reduc-
tion in CIN 2 and 3 achieved with 
the programme would be about 
72%. 
If HPV test is used 
with a sensitivity of 
90% for CIN 2 and 
3 lesions, and it is 
coupled with cryo-
therapy (which 
eliminates about 
80% of CIN 2 and 
3 lesions), the 
overall reduction in 
CIN 2 and 3 would 
be about 72%. 
HPV, cryotherapy,  
Article 18 
Sankaranarayanan, R., Nessa, A., 
Esmy, PO. and Dangou JM. 
(2012). Visual Inspection Methods 
for Cervical Cancer Prevention. 
Best Practice & Research in Clini-
cal Obstetrics & Gynaecology 26 
(2), 221-232 
Regularly repeated Pap smear 
screening linked with treatment 
has prevented millions of women 
from developing cervical cancer in 
high-income countries with well-
equipped and resourced 
healthcare services. 
Pap smear 
screening has de-
creased incidence 
of cervical cancer 
in high-income 
countries 
Cytology (Pap smear), 
high-income countries 
 ‘Screen-and-treat’ eliminates in-
vestigations to confirm a diagno-
sis before treatment and mini-
mises loss to follow up, delay in 
treatment and missed disease. A 
major concern is that a large num-
ber of women without precursor 
lesions will undergo cryotherapy..  
.. effective in preventing cervical 
neoplasia 
‘Screen-and-treat’ 
does not need 
complex infra-
structure. Concern 
is that many 
women will un-
dergo treatment 
unnecessarily  
.. effective in pre-
venting cervical 
cancer 
‘Screen-and-treat’, low-
resource countries 
 The major strengths of VIA in-
clude its affordability and feasibil-
ity in LMIC, possibility for repeat-
ing the test and to train screeners 
quite rapidly, wide availability of 
VIA has many ad-
vantages as well 
as disadvantages 
in LMIC. 
VIA, low-and-middle in-
come countries. 
Over-investigations and 
over-treatment. 
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dilute acetic acid, immediate test 
results, high potential for linkage 
with diagnosis and treatment and 
minimal infrastructure needs. The 
limitations include the subjective 
nature of the test, poor accuracy 
in postmenopausal and old 
women, low reproducibility, low 
specificity and high false positivity, 
leading to unnecessary anxiety, 
over-investigation and over-treat-
ment and lack of standardised 
methods for training, competency 
evaluation and quality assurance. 
The possibility that cost savings 
from low-test costs may be offset 
by excess expenditures caused 
by over-investigations and over-
treatment cannot be ruled out. 
Cost savings from 
low-test costs may 
be outweighed by 
excess expendi-
tures caused by 
over-investigations 
and over-treat-
ment. 
Article 19 
Ardahan, M. & Temel, AB. (2011) 
Visual inspection with acetic acid 
in cervical cancer screening. 
Cancer Nursing. 34(2):158-63. 
Data show that VIA is an accepta-
ble diagnostic tool for dysplasia 
and cervical cancer in underdevel-
oped countries 
VIA is acceptable 
method in devel-
oping countries 
VIA, developing count-
ries 
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Analysis of journal articles 
 
Author, year, 
country 
Purpose of 
the Study 
Sample Size 
(participants) 
Type of 
study 
Data Col-
lection and 
analysis 
Main Findings 
Almonte, M., Sas-
ieni, P. and Cuzick 
J. (2011) Incorpo-
rating human pap-
illomavirus testing 
into cytological 
screening in the 
era of prophylactic 
vaccines. Best 
Practice & Re-
search in Clinical 
Obstetrics & Gy-
naecology. 25 (5), 
617-29. 
To describe 
the current 
and potential 
use of HPV 
testing for 
vaccinated 
populations 
in countries 
with cytology-
based 
screening 
programmes.  
26 cross-sec-
tional studies, 8 
randomised trials 
Review Not men-
tioned 
Cytology-based screening 
programmes have been suc-
cessful in reducing cervical 
cancer in developed coun-
tries. HPV testing could be 
safely used in primary cervi-
cal screening. HPV tests and 
vaccines are expensive for 
less developed coun-
tries.The use of HPV test 
and cryotherapy might be 
the best option in women 
over 30–35 years of age. 
Ardahan, M. & 
Temel, AB. (2011) 
Visual inspection 
with acetic acid in 
cervical cancer 
screening. 
Cancer Nursing. 
34(2):158-63. 
United States 
 
To address 
the validity of 
VIA in cervi-
cal cancer 
screening by 
comparing 
results with 
colposcopy 
findings. 
Visual inspection 
with acetic acid 
and  Papanico-
laou test was ad-
ministered to 350 
women, col-
poscopy was ad-
ministered to 50 
women. 
Compa-
rative 
study 
Two ques-
tionnaires, 
Papanico-
laou and 
VIA tests, 
software 
package 
program. 
VIA findings were compared 
with Pap test findings: the 
sensitivity of VIA was 
82.14%, specificity was 
50.00%, positive predictive 
value was 67.64% and nega-
tive predictive value was 
68.75%. When the method 
of VIA was compared with 
colposcopy, VIA had a sensi-
tivity of 85.29%, specificity of 
68.75%, PPV of 85.29% and 
NPV of 68.75%. 
Binagwaho, A., 
Wagner, C., 
To describe 
the effect of 
19 references Review 
based 
Not men-
tioned 
The School based vaccina-
tion and community involve-
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Gatera, M,  Ka-
rema, C.,  Nutt, C 
and  Ngabo, 
F.(2012). Achiev-
ing high coverage 
in Rwanda’s na-
tional human pap-
illomavirus vac-
cination pro-
gramme. Bulletin 
of the  World 
Health Organ 
;90:623–628 
the vaccina-
tion in 
RWANDA 
on re-
gional 
longitu-
dinal 
study 
ment improved the vaccina-
tion coverage         
                     
                 
             
         
 
Chan, Z., Chan, 
T., Ng, K. and 
Wong, M.(2012). 
A Systematic Re-
view of Literature 
about Women's 
Knowledge and 
Attitudes Toward 
Human Papilloma-
virus (HPV) Vac-
cination. Public 
Health Nursing  29 
(6), 481-489 
To study and 
describe 
womens 
knowledge 
and attitudes 
toward HPV 
vaccination 
 
36 articles A Syste-
matic 
Review 
Databases: 
MEDLINE, 
CINAHL, 
the ISI Web 
of Science 
and the 
British 
Nursing In-
dex. 
Attitudes and intentions to-
ward HPV vaccination are 
generally positive. 
Knowledge, safety, cost and 
the efficacy of the vaccine. 
Many women lack 
knowledge about HPV and 
cervical cancer have an im-
pact on acceptance of the 
vaccine 
 
Denny, L. (2012) 
Cytological 
screening for cer-
vical cancer pre-
vention. Best 
Practice & Re-
search in Clinical 
Obstetrics & Gy-
naecology. 
26(2):189-96. 
To review the 
history of cy-
tological 
screening 
and the chal-
lenges of 
secondary 
prevention 
strategies 
Articles Review Not men-
tioned 
Well- implemented cytology-
based screening pro-
grammes have reduced cer-
vical cancer incidence and 
mortality. LBC and especially 
HPV have advantages over 
conventional cytology. HPV 
test and appropriate treat-
ment significantly improve 
detection of cervical cancer 
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Netherlands precursors and reduce cervi-
cal cancer. Cytology is cur-
rently recommended for use 
as a triage for HPV positive 
women or as a co-test with 
HPV testing for women over 
the age of 30 years. 
Fonseca, A., Fer-
reira, L. and Neto, 
G.(2013).Cost-ef-
fectiveness of the 
vaccine against 
human papilloma-
virus in the Brazil-
ian Amazon re-
gion. Revista Da 
Associacao 
Medica Bra-
sileira  59 (5), 
442-451 
Brazilia 
To assess 
the cost-util-
ity of the hu-
man papillo-
mavirus 
(HPV) vac-
cination on 
the preven-
tion of cervi-
cal cancer in 
the Brazilian 
Amazon re-
gion 
The target popu-
lation was 
preteen girls (12 
years of age), in-
dependent of pre-
vious sexual con-
tact or HPV infec-
tion. The cohort 
time horizon was 
lifetime.  
                 
             
         
             
             
 
Litera-
ture Re-
view 
mainly 
based 
on em-
pirical 
data of 
local 
and na-
tional 
studies 
 
A Markov 
cohort 
model was 
utilized as a 
decision 
analysis 
tool for the 
evaluation 
of cost-ef-
fectiveness 
and cost-
utility in 
preventive 
vaccina-
tion.     
The scenario of three Pap 
tests resulted in satisfactory 
calibration (base case). The 
addition of HPV vaccination 
would reduce by 35% the in-
cidence of cervical cancer 
(70% vaccination coverage).  
Vaccination has a favorable 
profile in terms of cost-utility, 
and its inclusion in the im-
munization schedule would 
result in a substantial reduc-
tion in incidence and mortal-
ity of invasive cervical can-
cer in the Brazilian Amazon 
region          
Hughes, C (2009) 
Cervical cancer: 
prevention, diag-
nosis, treatment 
and nursing care. 
Nursing Standard. 
23(27):48-56 
Update of 
cervical can-
cer; covering 
aspects of 
disease, 
prevention 
and treat-
ment. 
 
Not mentioned Review Keywords 
are based 
on the sub-
ject head-
ings from 
the British 
Nursing In-
dex. 
 
The prevention, diagnosis 
and treatment of cervical 
cancer needs primary and 
acute services. 
Women need health 
education of a vaccination 
programme, 
cervical screening and treat-
ment.  
Cervical screening pro-
grammes should be 
implemented worldwide to 
decrease the incidence of 
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cervical cancer and promote 
early treatment. 
El Hasnaoui, De-
marteau, Grana-
dos, Standaert 
and Detournay 
(2012)Public 
health impact of 
human papilloma-
virus vaccination 
on prevention of 
cervical cancer in 
France. Interna-
tional Journal of 
Public Health. 57 
(1), 149-58 
To evaluate 
the cervical 
cancer re-
duction at in-
dividual and 
population 
level follow-
ing different 
prevention 
strategies 
(age-specific 
vaccination 
and/or 
screening) in 
France. 
Every year during 
95 year period 
cohorts of 11 
year old girls in 
France were par-
ticipating to study 
Longitu-
dinal 
Study     
              
       
              
   
             
         
 
A lifetime 
Markov 
model, with 
11 health 
states, A 
screening 
module 
took into 
account the 
effects of 
detection 
and early 
treatment. 
Vaccination combined with 
screening substantially re-
duced the incidence of pre-
cancerous lesions and CC 
compared with screening 
alone. 
Vaccination was beneficial 
regardless of age at vaccina-
tion, but the greatest benefit 
was obtained with an early 
vaccination.  
The clinical results were the 
best for vaccination at 11-13 
years when lifetime horizon 
was considered, and for vac-
cination at 15-17 years for 
shorter observation period. 
Fu, L.,  Bon-
homme, 
L.,  Cooper, 
S.,  Joseph, J. 
and  Zimet 
G.(2014). Educa-
tional interven-
tions to increase 
HPV vaccination 
acceptance: a 
systematic review. 
Vaccine 32 (17), 
1901-1920 
To describe 
educational 
interventions 
to increase 
HPV vaccina-
tion ac-
ceptance 
                 
             
         
 
33 studies of 
HPV              
             
         
 
Review PubMed 
and Web of 
Science 
Databases. 
Random-
ized and 
nonran-
domized 
and quasi-
experi-
mental de-
signs  were 
included 
Well-designed studies ade-
quately powered to detect 
change in vaccine uptake 
were rare and generally did 
not demonstrate effective-
ness of the tested interven-
tion. 
There is not strong evidence 
to recommend any specific 
educational intervention for 
widespread implementation. 
Future studies are required 
to determine the effective-
ness of culturally- competent 
interventions reaching di-
verse populations. 
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Kane, M. 
(2012)Preventing 
Cancer with Vac-
cines: Progress in 
the Global Control 
of Cancer. 
Cancer Prevention 
Research; 5(1) 
24-29  
United States 
To describe 
the effective-
ness of HPV 
vaccine 
66 references Review 
article 
Not men-
tioned 
HPV vaccines are highly ef-
fective in preventing HPV in-
fection and precancerous le-
sions in women, and the 
quadrivalent vaccine also 
prevents genital warts in 
men and women and pre-
cancerous anal lesions in 
men. HPV is causing a grow-
ing proportion of oropharyn-
geal cancers, and HPV-re-
lated non cervical cancers   
Kim, Campos, 
O`Shea, Diaz and 
Mutyaba (2013) 
Model-Based Im-
pact and Cost-Ef-
fectiveness of 
Cervical Cancer 
Prevention in Sub-
Saharan Af-
rica.Vaccine.31 
(5), 60-72 
To estimate  
the popula-
tion-level 
health and 
economic im-
pact of HPV 
vaccination 
of pre-ado-
lescent girls 
Population and 
epidemiologic 
data from 48 
countries in sub-
Saharan Africa 
Quanti-
tative,a 
model-
based 
ap-
proach 
 
An existing 
individual-
based mi-
crosimula-
tion model, 
In addition 
empirically-
calibrated 
models for 
Uganda 
and South 
Africa were 
used to ob-
serve data 
from 
Uganda 
and South 
Africa 
HPV vaccination was cost-
effective when cost per vac-
cinated girl was below I$50. 
Vaccine prices may need to 
be even lower for vaccina-
tion programs to be afforda-
ble. 
Assuming 70% vaccination 
coverage, over 670,000 cer-
vical cancer cases would be 
prevented among women in 
five consecutive birth cohorts 
vaccinated as young adoles-
cents; over 90% of cases 
averted were projected to 
occur in countries eligible for 
GAVI Alliance support. 
 
Kling, M. and 
Zeichner, J. 
(2011)The Role of 
the Human Papil-
lomavirus (HPV) 
Not men-
tioned 
20 articles Litera-
ture Re-
view 
Not men-
tioned 
A worldwide HPV vaccine 
program would significantly 
reduce the spread of HPV 16 
and 18 and lower the inci-
dence of cervical cancer.  
For every five-year delay in a 
Appendix 2 
2 (4) 
 
 
Vaccine in Devel-
oping Countries. 
International Jour-
nal of Dermatol-
ogy 49 (4), 377-
379 
cervical cancer preven-
tion/detection program, there 
will be an additional 1.5–2.0 
million deaths. 
A global effort will be re-
quired to eliminate cervical 
cancer from developing 
countries. 
Monsonego J., 
Cortes., Greppe., 
Hampl., Joura, E 
and Singer, A. 
(2010). Benefits of 
Vaccinating 
Young Adult 
Women With a 
Prophylactic 
Quadrivalent Hu-
man Papilloma-
virus (types 6, 11, 
16 and 18) Vac-
cine. Vaccine 28 
(51), 8065-8072 
To describe 
the benefit of 
vaccinating 
young girls 
with quadri-
valent HPV 
vaccine 
66 publication Litera-
ture Re-
view of 
66 re-
veals 
Not men-
tioned 
There is strong epidemiologi-
cal and clinical support for 
vaccination programmes that 
target sexually active women 
in this age group to prevent 
HPV infection, and thus 
avert the development of 
HPV-related disease.  
The implementation of HPV 
vaccination programmes 
may benefit the development 
or awareness of cervical 
cancer prevention strategies 
and ultimately reduce the 
burden of cervical cancer 
and improve cervical cancer 
control. 
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Peate, I. (2009) 
The introduction of 
the human papillo-
mavirus vaccine - 
key issues. British 
Journal of Nursing 
18 (2), 86-89 
To provide 
insight into 
some of the 
issues sur-
rounding the 
introduction 
of the HPV 
vaccine into 
the national 
immunization 
programme.  
30 articles Litera-
ture Re-
view 
Not men-
tioned 
It is estimated that with the 
introduction of the HPV vac-
cination programme the lives 
of over 400 women per year 
will be saved in the UK. 
         
Vaccines are responsible for 
an increase in life expec-
tancy and quality of life – the 
HPV vaccine and its intro-
duction is likely to contribute 
to a significant increase in 
life expectancy as well as 
quality of life for future gen-
erations.  
Sankaranaraya-
nan, R., Anorlu, 
R., Sangwa-Lu-
goma, G and 
Denny, L.(2013). 
Infrastructure Re-
quirements for Hu-
man Papilloma-
virus Vaccination 
and Cervical Can-
cer Screening in 
Sub-Saharan Af-
rica. Vaccine 31 
(5), 47-52 
To update 
and describe 
the 
knowledge 
regarding the 
infrastructure 
requirements 
for HPV Vac-
cination and 
Cervical Can-
cer Screen-
ing in Sub-
Saharan Af-
rica 
48 references Review Not men-
tioned 
Vaccination along with the 
screening has made possi-
ble to reducing  
the high burden of cervical 
cancer in low- countries  
Political commitment, crea-
tive sources of financing and 
good planning in developing 
and augmentation of infra-
structure and human re-
sources for an integrated ap-
proach of vaccination, 
screening and treatment of 
women with cervical lesions 
is critically important for cost-
efficient delivery of the 
above-mentioned preventive 
interventions.  
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Van Kriekinge, G., 
Castellsague, X., 
Cibula, D. and De-
marteau, 
N.(2014). Estima-
tion of the poten-
tial overall impact 
of human papillo-
mavirus vaccina-
tion on cervical 
cancer cases and 
deaths.Vaccine 32 
(6), 733-739 
To estimate 
the effect of 
bivalent 
HPV-vaccine 
capability to 
reduce the 
incidence of 
cervical can-
cer 
Estimations of 
the incidence and 
mortality of cervi-
cal cancer from 
each country 
Review Estimation 
based on 
clinical trial 
and coun-
try-specific 
incidence 
data. Data 
on vaccine 
efficacy: 
PATRICIA 
trial of the 
AS04-adju-
vanted 
HPV-16/18 
vaccine.  
Cost- off-
sets: 5 
countries 
using coun-
try-specific 
unit cost 
data. 
HPV vaccination has a po-
tential to CC cases and 
deaths in countries world-
wide, with associated cost-
offsets due to reduced CC 
treatment. Cross-protection 
increased the estimated po-
tential number of CC cases 
and deaths prevented by 34 
and 18% in Africa and Oce-
ania. 
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Sankaranaraya-
nan, R., Nessa, 
A., Esmy, PO. and 
Dangou JM. 
(2012) Visual in-
spection methods 
for cervical cancer 
prevention. Best 
Practice & Re-
search in Clinical 
Obstetrics & 
Gynaecology. 
26(2):221-32. 
Netherlands 
To study 
whether vis-
ual screening 
is an effec-
tive approach 
for cervical 
cancer pre-
vention in 
low-and-mid-
dle-income-
countries by 
reviewing the 
feasibility, ac-
ceptability, 
safety, accu-
racy, efficacy 
and cost-ef-
fectiveness. 
Not mentioned Review Not men-
tioned 
Visual inspection with acetic 
acid is a suitable screening 
test for premenopausal 
women in low-resource set-
tings. Health care providers 
should use VIA and VILI for 
screening women aged 30-
59. VIA is the only feasible 
test in most sub-Saharan 
countries. Countries without 
cytology programmes can 
use VIA screening in demon-
stration programmes so that 
resources and infrastructure 
for screening can be devel-
oped in health services. 
Teitelman A-M., 
Stringer, M., Aver-
buch, T and 
Witkoski, A. 
(2009). Human 
papillomavirus, 
current vaccines, 
and cervical can-
cer prevention. 
Journal of Obstet-
ric, Gynecologic, 
& Neonatal Nurs-
ing 38 (1), 69-80 
Not men-
tioned 
86 releases Review 
article 
Not men-
tioned 
The new human papilloma-
virus vaccine advances cer-
vical cancer prevention; 
however, provider-recom-
mended screening with Pa-
panicolaou tests and lifestyle 
modifications are still 
needed. 
Wright TC Jr and 
Kuhn L (2011). Al-
ternative ap-
proaches to cervi-
To compare 
alternative 
approaches 
to cervical 
Articles and three 
large screening 
trials. 1: 57 study 
clusters random-
ised to a single 
Review Not men-
tioned 
Randomised-controlled trials 
conducted in developing 
countries clearly show de-
crease  in CIN2+ prevalence 
and incidence, with both 
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cal cancer screen-
ing for developing 
countries. Best 
Practice & Re-
search in Clinical 
Obstetrics & Gy-
naecology. 
26(2):197-208. 
Netherlands 
cancer pre-
vention and 
state out-
comes of 
three large 
screening tri-
als 
round of VIA car-
ried out by 
trained nurses 
and 57 study 
clusters random-
ised to a control 
group. 2: cluster-
randomised 
screening trial in-
cluded 131,746 
women aged 30–
59 years of age. 
3: Three years’ 
follow up of 
three-arm ran-
domised ‘screen-
and-treat’ trial, 
6,637 women 
aged 35–65 
years of age 
VIA-based and hr HPV-
based screening pro-
grammes. The benefits of hr 
HPV-based programmes 
seem to be greatly greater 
than the benefits of VIA-
based programmes.An inex-
pensive, point-of-care hr 
HPV diagnostic test should 
be developed and introduced 
widely. 
 
 
